Research complements the clinical activities of pharmacology and clinical toxicology in order to study the use of drugs, their efficacy and safety-with a clear focus on medication safety-in the context of real use in the general population. It is tasked with answering public health questions and improving patient care and safety through the design of studies of different types and methodology and participation in data collection, management and analysis of databases and registries.
At theIstituto di Scienze Farmacologiche della Svizzera Italiana , research activities are in the following areas:
- Study of the safety of COVID-19 vaccines.
- Safety of antineoplastic monoclonalantibody immune checkpoint inhibitors (through use of VigiBase®, the database of the World Health Organization, WHO, which collects spontaneous reports of adverse drug reactions).
- Safety of drug treatments in pregnancy (through use of VigiBase®).
- Safety of medication use in ischemic stroke patients (through use of stroke registries, national and international).
- Monitoring of recreational substance use resulting in acute toxicity and subsequent admission to the emergency department (through use of the European Drug Emergency Network, Euro-DEN, Plus database).
In addition, the ISFSI research unit participates in the following international projects:
- Drafting of initial recommendations for conducting pharmacovigilance studies in spontaneous reporting databases using disproportionality analysis.
- Data collection from EOC emergency rooms as an official center within the Euro-DEN Plus registry.
